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Abstract
As patents expire on innovator products, there is increasing interest in developing biosimilar products globally.
Biosimilars are not exact copies and are not considered generic versions of the reference product. They may
differ in strength, purity and contain different composition of isoforms and/or various glycosylation profiles, with
the consequent alterations in clinical efficacy or safety. Recently 2 new recombinant FSH preparations were introduced
to clinical practice following randomized controlled, phase 3 clinical trials. Both, Bemfola and Ovaleap® were referred to
the FSH innovator product Gonal-f™ (Follitropin alpha), and were found to yield an equivalent number of oocytes
(primary end-point), following a long GnRH agonist suppressive protocol in “ideal” patients, i.e., young, normal
responders. However, a closer look at these RCTs reveals a non-significant 4 % difference in clinical and ongoing
pregnancy rates, in favor of Gonal f over the biosimilar products, accompanied by half the incidence of OHSS (2.9 vs 5.
2 %, respectively). These studies were underpowered with reference to pregnancy rates, Thus, we believe that further
comparative studies are needed in additional patient populations, e.g.,older,, poor responders, patients with repeated
IVF failures and/or polycystic ovary syndrome, before the universal implementation of biosimilar products for clinical
use. Biosimilars are actually a regulatory synonym, facilitating a fast track introduction of a FSH preparation to the COH
armamentarium. We therefore recommend against interchanging or substituting innovator and biosimilar agents in
clinical practice, and believe that the decision whether to use an innovator or a biosimilar product, should be reserved
to the discretion of the treating physician. Furthermore, we believe the time has come that the measurement of the
biological activity of FSH in humans should require other methods rather than the Steelman-Pohley assay, such as the
determination of dose–response curves in defined populations of women with well-defined outcomes during COH in
preparation for ART.
Introduction
As patents expire on innovator products, there is
increasing interest in developing biosimilar products
globally. The FDA describes biosimilars as biologic
products that are “highly similar to the reference
product not with-standing minor differences in clinic-
ally inactive components and that there are no clinic-
ally meaningful differences between the biologic
product and the reference product in terms of safety,
purity, and potency of the product” [1]. This defin-
ition makes it clear that biosimilars are not identical
molecules or “generics” for biologic agents. They may
still differ in strength, purity and contain different
composition of isoforms and/or various glycosylation
profiles, with consequent alterations in clinical effi-
cacy or safety [2, 3]. Therefore, the manufacturer of
the biosimilar product is required to conduct phase
III randomized controlled trials (RCT) aiming to
demonstrate that those changes do not adversely
affect the identity, purity,or potency of the potentially
approved biologic product [4]. Notwithstanding, most
health organizations do not consider biosimilar to be
interchangeable with innovator product and recom-
mend against substituting innovator and biosimilar
agents in clinical practice.
FSH has served for decades as the active component
in different pharmaceutical preparations for treatment of
infertility, e.g., to induce ovulation in oligo-anovulatory
patients or to stimulate the development and maturation
of a large number of follicles in patients undergoing con-
trolled ovarian hyperstimulation (COH) for in vitro
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fertilization (IVF). While urinary FSH (uFSH) was used
as the active material of the early pharmaceutical prepa-
rations used, recombinant FSH (rFSH) preparations pro-
duced in Chinese hamster ovary (CHO) cells, or human
cell lines have become available later on.
FSH isoforms
It is well known that not only the levels of the FSH
change during the different menstrual phases but also
the composition of its different FSH isoforms. While
Padmanabhan et al. [5] demonstrated that the rate of
acidic isoforms in the serum is the lowest during the
preovulatory and ovulatory phase; Ulloa-Aguirre et al.
[6] found that the basic isoforms are secreted before
ovulation. Zambrano et al. [7] have demonstrated that
the proportion of the acidic isoform is higher during the
early to mid-follicular phase compared to the preovula-
tory phase.
When FSH activity is measured in vitro, acidic iso-
forms of FSH have a lower activity than the more basic
isoforms. In contrast, when the activity is measured in
vivo, the acidic isoforms of FSH have a higher activity
than the basic isoforms of the same preparation thus,
reflecting higher affinity and efficacy of the basic iso-
forms, with shorter half-life in vivo.
Measurement of FSH preparations activity
The activity of the FSH preparations can be measured in
vitro or in vivo. Measurement of FSH activity in vitro
can be performed by testing the efficiency of the binding
of FSH to the membrane receptor, or by measuring the
ability of FSH to stimulate enzymes or secondary mes-
sengers within target cells in culture. Measurement of
the biological activity in vivo can be performed in ani-
mals and in humans. Since the 1950s, the most common
and standard model for measuring the biological activity
of FSH preparations in animals is the Steelman-Pohley
assay, which is performed in two groups of immature
female rats with low endogenous FSH level and is based
on measuring ovary mass augmentation [8].
The activity of FSH preparations is influenced by the
clearance rate of the hormone, which depends on the
metabolism of different living organisms. Furthermore,
in humans, exogenous FSH is distributed within the
extracellular fluid space and the apparent volume of
distribution and clearance are both proportional to body
weight. Thus, body weight is inversely associated with
follicular development and serum levels of E2 in re-
sponse to FSH dosage. It is therefore not surprising that
the activity, as determined in rats, will not be reliable in
other organisms, as was clearly evident by De Leeuw et
al. [9]. While comparing the biological availability and
the half-life of rFSH and uFSH, they could not observed
any differences between these two preparations, after
calibration of an identical amount of International
Units using the Steelman-Pohley assay, when they
were injected into rats. However, a difference was
found when injected into dogs [9]. They therefore
concluded that the Steelman-Pohley assay is not a
suitable model for predicting the biological activity of
FSH in animals other than rats.
The fact that two FSH preparations contain the
same number of activity units according to the
Steelman-Pohley assay does not indicate anything re-
garding the number of moles of FSH in each of the
preparations. Comparison of the efficacy of two prepara-
tions should be performed on a molar basis. For example,
already in 2000, the European Health Authorities ap-
proved a change of the initial recommended dosage of the
Puregon® from 75 IU to 50 IU. The reason for the amend-
ment was that, the actual dosing advice was based on the
dosages used for urinary FSH. Even though the two prepa-
rations had the same IU it was found that the Puregon® is
more efficacious than urinary FSH and therefore may re-
quire a lower dose [10]. Moreover, administration of iden-
tical bioactive doses (based on the Steelman-Pohley in
vivo rat bioassay) of rhFSH from a cell line of human fetal
retinal origin and follitropin α resulted in slower clearance
and thus, significantly higher follicular and endocrine re-
sponses as well [11]. A difference in the clearance of
between rats and humans was believed to be the most
likely explanation for the limited prediction of the in
vivo rat bioassay for its potency in humans. There-
fore, this novel recombinant product was dosed in
microgram (μg) of protein content rather than in IU
of biological activity.
These examples illustrate that the time has come that
the measurement of the biological activity of FSH in
humans should be required by other methods instead
of the Steelman-Pohley assay. Specifically we believe
that the determination of dose- response curves in well
characterized populations of women for well-defined
outcomes during COH in preparation for ART is needed
Controlled ovarian hyperstimulation
The challenge with which infertility specialists are
continuously encountering is tailoring patient’s treat-
ment, e.g., the need for increased ovarian stimulation
and recruitment of follicles on the one hand, while
preventing the ovarian hyperstimulation syndrome
(OHSS), on the other hand. “Tailoring” the treatment
is based mainly on determining the initial daily FSH
dose, which is based on several parameters, including
patient’s age, body mass index (BMI), the etiology of
infertility and measures of ovarian reserve [Day 3
serum FSH, antral follicle count (AFC) and/or random
serum anti-mullerian hormone(AMH) level]. Further-
more, the daily FSH dose is adjusted according to the
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patient’s response to COH, as reflected by monitoring
serum E2 levels and the number and size of the follicles
recruited [12].
FSH preparations
Regardless of the source of FSH, the protein structure
is identical, while the glycosylation patterns, which re-
sult from differences in posttranslational modifications,
vary. When a FSH preparation is separated into two or
more preparations, those preparations with a higher de-
gree of sialylation, i.e., acidic preparations, will have a
longer half-life and higher in vivo activity, as compared
to the basic preparations with a lower degree of sialyla-
tion. Mulders et al. [13] have examined the in vivo ac-
tivity of different isoforms of rFSH in rats, which were
separated by isoelectric focusing (IEF). They found that
acidic isoforms were 100 to 200 times more active than
basic isoforms. Similarly, D’Antonio et al. [14] exam-
ined the clearance rate of acidic isoforms compared to
basic isoforms originating from the same rFSH prepar-
ation using a rat model. The acidic isoforms were found
to have a lower clearance rate, which supports their
higher biological activity in vivo (as determined by the
Steelman-Pohley assay). In the discussion, the authors
cited other studies demonstrating that the sialic acid
content determines the clearance rate, the higher the
sialic acid content in the molecule, the lower the clear-
ance rate, and the half-life and biological activity in vivo
increase accordingly. Similarly, Chappel [15], in a publi-
cation on the use of gonadotropin isoforms in different
pharmaceutical preparations, proposed using acidic iso-
forms at the beginning of the treatment, in order to re-
cruit follicles, and later to change to basic isoforms in
order to control the number of follicles and prevent
OHSS. Moreover, when a large number of follicles are
required, the use of acidic isoforms, with the longer
half-life is recommended.
Many studies and multiple meta-analyses comparing
different FSH preparations have yielded conflicting re-
sults for ovarian stimulation variables and pregnancy
rate [16, 17]. When examining the different commercial
FSH preparations, the isoforms present in uFSH are
more acidic than those in rFSH [18]. Interestingly, based
on the natural distribution of FSH isoforms during the
follicular phase of the menstrual cycle, Gurgan et al. [19]
have demonstrated favorable outcomes and improved ef-
ficacy, while using a sequential administration of uFSH
followed by rFSH compared with either FSH preparation
alone. Moreover, when prospectively evaluating the
efficacy of a protocol that mimics the physiological shift
form an acidic to a less acid FSH isoform during oocyte
maturation, Gerli and Di Renzo [20] could demonstrate
that the combined protocol (hFSH + rFSH) resulted in
significantly less IU of FSH necessary for ovarian
stimulation together with shorter stimulation days and
with higher number of oocyte yield, embryo quality, im-
plantation and pregnancy rates.
Biosimilar FSH preparations
Gonal-f™ (Follitropin alpha, Merck Serono S.A.) is the
FSH innovator products that all the recently biosimi-
lar products were referred and compared to. When
Gonal-f™ was compared to a potential biosimilar,
Grass et al. could demonstrate that the two r-hFSH
preparations have apparently identical polypeptide
chains but a somewhat different glycosylation pattern
[21]. In particular, for the biosimilar, the N-terminal
glycosylation site of the β-chain contained a higher
percentage of tri- and tetra-antennary glycans and of
N-acetyllactosamine repeats compared with Gonal-f™.
A discrimination that may matter as under sialylation
and increased numbers of antennae have an opposite
effect on the biospecific activity of r-hFSH [22], with
the consequent relevance for its biological activity.
The aforementioned different isoforms composition
dictates to the manufacturer of the biologic product to
conduct a complex and comparability studies, aiming
to demonstrate that those changes do not adversely
affect the purity, potency or the identity of the product.
Following those studies the products may be intro-
duced to clinical practice and the most crucial issue is
whether they are identical to the innovator product or
just another product. Whether they are “identical twins
or siblings” will lead their being interchangeable, or
not, with the innovator products.
RCT comparing Gonal-f™ to a biosimilar products
Bemfola (follitropin alfa) (Finox AG, Switzerland), a new
recombinant FSH, was recently introduced to clinical
practice following an assessor-blinded, randomized,
parallel group, multi-center, phase 3 trial aimed to test
equivalence in the number of retrieved oocytes, with a
power of 90 %, an alpha error of 2.5 % and a pre-
determined clinical equivalence margin of ±2.9 oocytes
for the relevant population [23]. Normal responders,
young, good prognosis patients underwent the long
GnRH agonist suppressive protocol with a daily FSH
dose of 150 IU. Compared with Gonal-f, Bemfola treat-
ment resulted in a statistically equivalent number of re-
trieved oocytes. Furthermore, other (but not primary
end-points) observations were the similar clinical preg-
nancy rate per embryo transfer in first and second cycles
with no difference in severe OHSS between treatment
groups. The authors concluded that Bemfola can be an
appropriate alternative in ovarian stimulation protocols.
A closer look at this RCT [23] (Table 1) reveals that
while receiving the same daily and total rFSH doses, the
Gonal-f group achieved non significantly more oocytes
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(10.7 vs 10.6, respectively), despite lower peak E2 levels
and lower cancellation rate (7704 vs 8982pmol/L and
0.8 % vs 2.0 %, respectively) with the consequent de-
creased incidence of OHSS (3.3 % vs 5.6 %, respect-
ively). Moreover, while clinical and ongoing pregnancy
rates were non-significantly higher in the Gonal-f group
(44.7 vs 36.1 and 41.5 vs 33.7, respectively), power ana-
lyses calculation reveals 44.6 % and 43.2 %, respectively,
for the present sample sizes and an α − error of 5 %.
Just emphasizing, that this study was underpowered
and was not designed to refer to pregnancy rates. Of
note, patients receiving Bemfola had a significantly
higher chemical pregnancy rate, that did not develop to
clinical pregnancy (10.4 vs 4.1 %, p < 0.02, respectively).
Ovaleap® (follitropin alfa) is another new r-hFSH
manufactured in CHO cells that has been developed
as a biosimilar to Gonal-f. It was introduced to clin-
ical practice following a multinational, randomized,
active-controlled, assessor-blinded, parallel group pa-
tient study [24], aimed to test for the number of oo-
cytes retrieved, as the primary efficacy endpoint, with
a 90 % power and a two-sided level of α = 0.05. As
with the previous Bemfola study, normal responders,
young, good prognosis patients underwent the long
GnRH agonist suppressive protocol with a daily FSH
dose of 150 IU. The mean number of oocytes re-
trieved was equivalent between the two groups with
comparable safety profiles.
Here again, a closer look at this RCT [24] (Table 1) re-
veals that while receiving the same daily and total rFSH
doses, the Gonal-f group achieved non significantly
lower peak E2 levels and lower cancellation rate (9534 vs
10070pmol/L, respectively) with the consequent de-
creased incidence of OHSS (2.7 % vs 4.5 %, respectively).
Moreover, clinical, ongoing pregnancy and live birth
rates were higher in the Gonal-f group (Table 1), how-
ever, non-statistically significant, due to the insufficient
sample size.
Gathering the data from the aforementioned studies
[23, 24] (Table 2), comparing Gonal f vs the biosimilar
products, revealed non-significant 4 % difference in
clinical and ongoing pregnancy rates, in favor of Gonal f
over the biosimilar products, with half the incidence of
OHSS (2.9 vs 5.2 %, respectively).
Conclusions
The aforementioned figures were obtained while treating
the “ideal” patients, young, good responder with the best
Table 1 Data from the Bemfola and Ovaleap RCTs [23–24)

















# of patients 249 123 146 153
BMI (kg/m2) 22.7 22.4 22.6 22.8
FSH (IU) 6.9 6.9 7.3 7
Duration of stimulation (days) 10.6 10.7 9.7 9.3
Total dose of FSH used 1555 1569 1614 1536
E2 (pmol/L) 8982 7704 9534 10070
OHSS 14 0.056 4 0.032 4 0.027 7 0.045
# oocyte 10.7 10.4 12.1 12.2
#ET 1.5 1.6 NA NA
FR (%) 66.1 64 NA NA
IR (%) 31.8 36.7 NA NA
Biochemical pregnancy 116 0.465 60 0.487 60 0.410 58 0.379
Clinical pregnancy 90 0.361 55 0.447 52 0.356 43 0.281
Ongoing pregnancy 84 0.337 51 0.414 49 0.335 42 0.274
LBR NA NA 47 0.321 41 0.267
Chemical pregnancy 26 0.104 5 0.040 8 0.054 15 0.098
Table 2 Gathered data from the Bemfola and Ovaleap RCTs
[23 + 24]









# of patients 402 269
OHSS 21 0.052 8 0.029
Biochemical pregnancy 166 0.412 120 0.446
Clinical pregnancy 142 0.353 107 0.397
Ongoing pregnancy 133 0.330 100 0.371
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prognosis. Therefore, further comparative studies are
needed in other patient populations that are encountered
during routine daily clinical practice, e.g., older, poor re-
sponders, patients with repeated IVF failures or high re-
sponders, such as those with polycystic ovary syndrome,
before the universal implementation of biosimilar prod-
ucts to clinical use. Biosimilars are not exact copies, and
are not considered generic versions of the reference prod-
uct. They are actually a regulatory synonym, facilitating a
fast track introduction of a FSH preparation to the COH
armamentarium. We believe the time has come that the
measurement of the biological activity of FSH in humans
should require other methods than the Steelman-Pohley
assay, such as the determination of dose–response curves
for well characterized patient populations for well-defined
outcomes during COH in preparation for ART. We there-
fore recommend against interchanging or substituting in-
novator and biosimilar agents in clinical practice, and
believe that the decision whether to use an innovator or a
biosimilar product, should be reserved to the discretion of
the treating physician. This recommendation is in line
with the recently published Australian Public Assessment
Report [25], instructing the sponsor of a biosimilar prod-
uct to add a ‘Dear Healthcare Professional Letter’. A letter
that “should at least contain.... A statement that although
Bemfola is considered biosimilar it is not interchangeable
with other follitropin alfa products on an individual pa-
tient basis”.
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